Fennec Pharmaceuticals Inc. (FENC)

Over the past six months, Fennec's stock has been impacted by several events. Record annual revenue for FY2025 and Q4 2025 net product sales were reported, but the stock dropped due to concerns about profitability and dilution. Inducement grants led to a stock price increase. An investigator-sponsored study announcement resulted in a stock price decrease. The acceptance of abstracts at the ASCO Annual Meeting led to a stock price increase. The announcement of the Q1 2026 earnings release saw a positive move. An underwritten registered public offering of common shares was priced, with net proceeds intended for debt repurchase, working capital, and general corporate purposes. Fennec paid down debt, resulting in no debt outstanding as of December 31, 2025.

There is an indication of demand seasonality for Fennec Pharmaceuticals' products. A decrease in cash and cash equivalents was primarily due to seasonal spending patterns in the first quarter of the year, suggesting that demand or related financial activities may fluctuate with the seasons.

Fennec Pharmaceuticals, Inc. is a commercial-stage specialty pharmaceutical company focused on combating chemotherapy-induced hearing loss in cancer patients. Their primary product is PEDMARK®, a sodium thiosulfate injection indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric cancer patients. The company focuses on commercializing PEDMARK® in North America for its FDA-approved pediatric indication and also commercializes the same active therapy in certain international markets under the brand name PEDMARQSI®.

Fennec Pharmaceuticals primarily operates in the United States, where PEDMARK® received FDA approval in September 2022. PEDMARQSI® has received European Commission approval in June 2023 and United Kingdom approval in October 2023. Fennec has an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. to commercialize PEDMARQSI® in Europe, the U.K., Australia, and New Zealand. PEDMARQSI® is currently commercially available in the U.K. and Germany. The company also has a clinical trial in Japan, with results expected in the second half of 2025.

Fennec Pharmaceuticals has a positive brand reputation centered on its commitment to addressing ototoxicity in cancer patients. PEDMARK® has received significant regulatory approvals, including FDA approval in the U.S., European Commission approval, and U.K. approval for PEDMARQSI®. The company has reported record annual revenue and strong demand for PEDMARK®, indicating successful market penetration. Fennec's focus on expanding real-world validation of PEDMARK® and its revamped Fennec HEARS® patient support program contribute to its positive image.

Fennec Pharmaceuticals Inc. has 99 institutional owners and shareholders holding a total of 16,019,002 shares, representing 45.07% of the stock. Fennec Pharmaceuticals insiders own 995.93%, and retail investors own 0.00%. Major institutional owners include Southpoint Capital Advisors LP, Rosalind Advisors, Inc., and BlackRock, Inc. Southpoint Capital Advisors LP is also identified as the largest individual Fennec Pharmaceuticals shareholder. Insider buying has exceeded insider selling in the past three months.